title: Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia.
authors.affiliation: Dartmouth-Hitchcock Medical Center, One Medical Center Dr, Lebanon, NH 03756, USA. britt.m.holderness@hitchcock.org
authors.forename: Britt M
authors.initials: BM
authors.lastname: Holderness
authors.forename: Saurabh
authors.initials: S
authors.lastname: Malhotra
authors.forename: Norman B
authors.initials: NB
authors.lastname: Levy
authors.forename: Alexey V
authors.initials: AV
authors.lastname: Danilov
mesh_terms: D000079963:Brentuximab Vedotin; D006801:Humans; D018796:Immunoconjugates / Q000276:immunology / Q000378:metabolism*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D016400:Lymphoma, Large-Cell, Immunoblastic / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D011379:Prognosis; D014057:Tomography, X-Ray Computed
chemical_list: D018796:Immunoconjugates; D000079963:Brentuximab Vedotin